BIOAGE LABS, INC. Operating Expenses
BIOAGE LABS, INC. (BIOA) reported Operating Expenses of $31.78 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-05
- BIOAGE LABS, INC. operating expenses for the quarter ending 2026-06-30 was $31.78M, a 16.93% increase year-over-year.
- BIOAGE LABS, INC. operating expenses for the quarter ending 2026-03-31 was $28.15M, a 57.27% increase year-over-year.
- BIOAGE LABS, INC. operating expenses for the quarter ending 2025-12-31 was $31.50M, a 24.21% increase year-over-year.
- BIOAGE LABS, INC. operating expenses for the quarter ending 2025-09-30 was $25.19M, a 1.79% increase year-over-year.
- BIOAGE LABS, INC. operating expenses for fiscal 2025 was $101.78M, a 30.16% increase from fiscal 2024.
- BIOAGE LABS, INC. operating expenses for fiscal 2024 was $78.19M, a 61.56% increase from fiscal 2023.
- BIOAGE LABS, INC. operating expenses for fiscal 2023 was $48.40M.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $31.78M 10-Q · filed 2026-08-05 | $59.93M 10-Q · filed 2026-08-05 | $91.43M derived: sum of 3 quarters · filed 2026-08-05 | $116.63M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $28.15M 10-Q · filed 2026-05-08 | $59.65M derived: sum of 2 quarters · filed 2026-05-08 | $84.84M derived: sum of 3 quarters · filed 2026-05-08 | $112.03M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $31.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | $56.70M derived: sum of 2 quarters · filed 2026-03-24 | $83.88M derived: sum of 3 quarters · filed 2026-08-05 | $101.78M 10-K · filed 2026-03-24 |
| 2025-09-30 | $25.19M 10-Q · filed 2025-11-06 | $52.38M derived: sum of 2 quarters · filed 2026-08-05 | $70.27M 10-Q · filed 2025-11-06 | $95.64M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $27.18M 10-Q · filed 2026-08-05 | $45.08M 10-Q · filed 2026-08-05 | $70.44M derived: sum of 3 quarters · filed 2026-08-05 | $95.19M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $17.90M 10-Q · filed 2026-05-08 | $43.26M derived: sum of 2 quarters · filed 2026-05-08 | $68.01M derived: sum of 3 quarters · filed 2026-05-08 | $83.28M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $25.36M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | $50.11M derived: sum of 2 quarters · filed 2026-03-24 | $65.38M derived: sum of 3 quarters · filed 2026-03-24 | $78.19M 10-K · filed 2026-03-24 |
| 2024-09-30 | $24.75M 10-Q · filed 2025-11-06 | $40.02M derived: sum of 2 quarters · filed 2025-11-06 | $52.83M 10-Q · filed 2025-11-06 | $66.43M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $15.27M 10-Q · filed 2025-08-06 | $28.08M 10-Q · filed 2025-08-06 | $41.68M derived: sum of 3 quarters · filed 2025-08-06 | $51.56M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | $12.81M 10-Q · filed 2025-05-06 | $26.41M derived: sum of 2 quarters · filed 2025-05-06 | $36.30M derived: sum of 3 quarters · filed 2025-05-06 | |
| 2023-12-31 | $13.60M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $23.48M derived: sum of 2 quarters · filed 2025-03-20 | $48.40M 10-K · filed 2025-03-20 | |
| 2023-09-30 | $9.89M 10-Q · filed 2024-11-07 | $34.80M 10-Q · filed 2024-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |